Italian Multicenter Database for Open Conversions After EVAR
Launched by AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA · Mar 5, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the best ways to treat complications that can happen after a procedure called endovascular abdominal aneurysm repair (EVAR). When patients have problems due to EVAR that can't be fixed by other endovascular methods, doctors have two main options: a late open conversion (LOC) or a semi-conversion (SC). LOC involves removing part or all of the original graft used in the repair, while SC means performing surgery to fix a specific issue without removing the graft. The goal of this study is to gather information on these two types of surgeries from multiple centers and to see how well they work in both the short and long term.
If you or a family member are between the ages of 65 and 74 and have had complications from EVAR that require open or laparoscopic surgery, you may be eligible to participate in this trial. However, if you have undergone other types of procedures not directly related to the graft, such as certain bypass surgeries, you would not qualify. Participants can expect to contribute to valuable research that may help improve future treatments for similar complications. The study is not yet recruiting, but it aims to provide important insights into the outcomes of different surgical approaches for EVAR complications.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • open or laparoscopic surgery for EVAR complications, with or without endograft explantation
- Exclusion Criteria:
- • endovascular reinterventions
- • extra-anatomical bypass surgery (e.g. femoro-femoral crossover bypass) not associated with direct aorta/endograft surgery
About Azienda Ospedaliero Universitaria Di Parma
Azienda Ospedaliero-Universitaria di Parma is a leading hospital and university institution in Italy, dedicated to advancing medical research and patient care through innovative clinical trials. With a strong emphasis on collaboration between healthcare professionals and academic researchers, the organization aims to enhance therapeutic interventions and improve health outcomes across various medical fields. Its commitment to excellence in clinical research is reflected in its state-of-the-art facilities, multidisciplinary approach, and adherence to rigorous ethical standards, positioning it as a pivotal contributor to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parma, , Italy
Patients applied
Trial Officials
Paolo Perini, MD
Principal Investigator
Parma University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials